Aster Prime Hospital does not offer any sort of employment in exchange for payment of money for any purpose whatsoever. If you receive any similar kind of offer from anyone representing Aster Prime Hospital, please send an email with the intimation and related documents to [email protected].
Dr Manuprasad Oncologist

Dr. Manuprasad A

Consultant - Medical Oncology

MD( General Medicine), DM( Medical Oncology)
Speciality
Medical Oncology
Languages
English, Malayalam, Tamil
Overview

Dr. Manuprasad completed his training in Internal Medicine and Medical Oncology from the premier institutes in the country. He has extensive experience in the clinical and multidisciplinary care of patients with various cancers and is well-versed in the use of chemotherapy, targeted therapy, and immunotherapy. Apart from the clinical work he is also actively involved in clinical research in Oncology. He has multiple publications in indexed journals and has presented at national and international conferences. He has been a principal investigator for multiple investigator-initiated and industry-sponsored clinical trials. Before joining Aster MIMS he was serving as an Additional Professor in the Department of Clinical Hematology and Medical Oncology in Malabar Cancer Centre,Thalssery .He is a member of the American Society Of Medical Oncology (ASCO), European Society of Medical Oncology (ESMO), Indian Society Of Medical and Paediatric Oncology (ISMPO) and Indian Cooperative network in Oncology (ICON)

Area of expertise
  • Chemotherapy for solid tumors and hematological malignancies
  • Immunotherapy
  • Medicine Clinical trials
  • Hematopoietic stem cell transplant
Awards and recognitions
  • Gold medals in General medicine,General Surgery and Ophthalmology During MBBS ( Government Medical College ,Thiruvananthapuram) 
  • Professor Ramachandran Memorial Gold medal in Pathology (2006)- 
  • Best outgoing student Government Medical College Thiruvananthapuram (2008)
  • Best outgoing student General Medicine Govt Medical college Kozhikode ( 2013)
  • Merit grant for Advanced Course in Biomarkers for Precision Medicine conducted by ESMO (European Society Of Medical Oncology) in October 2022 at Singapore
  • Best abstract award in the 12th annual conference of Indian Society of study in Lung cancer 2021 (NALLCON)
  • European Society Of Medical Oncology merit travel grant for ESMO ASIA 2022 8) Best Poster Award – in the category of Genitourinary - Prostate Cancer in European society of Medical Oncology Asia Conference 2022 held at Singapore

Publications

  • Experience with Nilotinib in Indian patients with CML Manuprasad, A., Ganesan, P., Ganesan, T.S. et al. Indian J Hematology and Blood Transfusion (2017). https://doi.org/10.1007/s12288-017-0877-x 
  • Hepatoblastoma: 16-years’ experience from a tertiary cancer centre in India Manuprasad A, Venkatraman R Paediatric Hematology Oncology Journal (Jan 2018) https://doi.org/10.1016/j.phoj.2018.01.002
  • Health related quality of life in patients with multiple myeloma on novel agents – report from a tertiary cancer centre in rural India. Vineetha Raghavan, Manuprasad A, PB Sajeev Kumar, Zoheb Raj, P K Shenoy, Chandran K Nair Cancer Res Stat Treat 2018;1:92-5 
  • Short course adjuvant trastuzumab in breast cancer :Experience from a tertiary cancer centre in rural India. Manuprasad A,Shenoy P K,Vinin NV et al .Cancer Res Stat Treat 220:3:69-73
  • Infection at diagnosis-a unique challenge in acute myeloid leukemia treatment in developing world . Pandian J, Raghavan V, Manuprasad A, Shenoy PK, Nair CK. Support Care Cancer. 2020;10.1007/s00520-020-05379-z. doi:10.1007/s00520-020-05379-z
  • Docetaxel-induced lung injury: An under-recognized complication of a commonly used chemotherapeutic agent. Manuprasad A, Ganesan P, Mahajan V, Ganesan TS, Radhakrishnan V, Dhanushkodi M, Sagar TG. Indian J Med Paediatr Oncol 2019;40:208-11
  • Toxicity profile of weekly regimen of paclitaxel in patients with non-metastatic breast cancer-a real world experience. Praveen Kumar Shenoy , Isharath Ebrahim , Anitha Mary Skaria , Manuprasad A Oncology and Radiotherapy Vol. 15 Iss.2:009-012
  • Gemcitabine, dexamethasone, and cisplatin salvage in relapsed lymphomas: A single institutional experience. Manuprasad A, Shenoy PK, Raghavan V, Shiljina K M, Nair CK Cancer Res Stat Treat 2020;3:13-8
  • Unmet need in patients with multiple myeloma-a cross sectional study from India . Avaronnan Manuprasad, Vineetha Raghavan, Sajeev Kumar PB, Zoheb Raj, Praveen Kumar Shenoy, Chandran K Nair Oncology and Radiotherapy 1 (46) 2019: 090-094
  • Impact of active tuberculosis on treatment decisions in cancer. Chandran K. Nair, Manuprasad Avaronnan, Praveen Kumar Shenoy, Vineetha Raghavan, Priya Jayarajan, Parthiban Rudrapathy, Karthickeyan Duraisamy, Satheesan Balasubramanian, Current
  • Problems in Cancer, 2020,100643ISSN 0147 0272,https://doi.org/10.1016/j.currproblcancer.2020.100643
  • The utility of day 14 bone marrow response assessment in patients undergoing acute myeloid leukemia induction: A single-institution retrospective experience. Manuprasad A, Raghavan V, Shenoy PK, Krishnan A, Nair CK. Cancer Res Stat Treat 2021;4:628-33
  • Fear of Recurrence and Somatic Symptom Severity in Multiple Myeloma Patients: An Institution-Based Cross-Sectional Study. Praveen Kumar Shenoy V P,Vineetha Raghavan,Avaronnan Manuprasad,Sajeev Kumar P. B.,Zoheb Raj,Chandran K. Nair. Indian J Med Paediatr Oncol 2022 4304 355-360 DOI DOI 101055s-0042-1755302. 
  • Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India. CK Nair, AR Kurup, A Manuprasad, PK Shenoy, V Raghavan Journal of Cancer Research and Therapeutics 17 (4), 938 14) Neoadjuvant Platinum Based Chemotherapy in Triple Negative Breast Cancer-Preliminary Experience from A Tertiary Cancer Centre. Praveen Kumar Shenoy, Joneetha Jones, Vinin N V, Manuprasad A, Geetha M And Priya Rathi Int J Pharm Bio Sci Vol 12 Issue 2 2021 April-June Pages71-77.
  • Treatment pattern and outcomes in patients with uncommon or compound EGFR mutations in India: CRSF 2020-03 study. Manuprasad Avaronnan, Rushabh Kothari, Avinash Talele, Vikas Talreja, Gautam Goyal, Nirmal Vivek Raut, and Ashay Karpe . Journal of Clinical Oncology 2022 40:16_suppl, e21034-e21034
  • 163P Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country M. Avaronnan, M. et al. Annals of Oncology, Volume 33, S1498 
  • 24P Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib. Mathew, S.P., Manuprasad Avaronnan,VP Shenoy,Nandini devi R Annals of Oncology, Volume 33, S1439 
  • Utility of annual surveillance mammography in patients with treated breast cancer- A single institutional experience from India. Manuprasad Avaronnan, Sreelakshmi Soman,Satheesh Babu TV,Geetha Muttath Oncologyand Radiotherapy © 16 (12) 2022: 089-092 •
  • Oral metronomic chemotherapy as a feasible preoperative therapy in advanced resectable oral cavity squamous cell carcinomas – a preliminary experience. Shenoy V
  • P Praveen Kumar, Manuprasad Avaronnan, Babu Sajith, Aravind Sithara, Narayanan Vinin N, Nayanar Sangeetha, Balasubramanian Satheesan ecancer 16 1425 (2022)